Shunt Therapy Falters in HF Without Reduced EF: REDUCE LAP-H

The trial was 'neutral' but said to have produced important mechanistic insights that could guide the investigational heart failure device therapy to success in the future.

Related Keywords

New York , United States , Australia , Japan , Boston , Massachusetts , Minnesota , Mayo Clinic In Rochester , Chicago , Illinois , Tufts Medical Center , America , American , Sanofi Pasteur , Navink Kapur , Elucid Bio , Edwards Lifesciences , Eli Lilly , Glaxosmithkline , Amgen , Boehringer Ingelheim , Northwestern University Feinberg School Of Medicine , Novartis , Pfizer , Astrazeneca , Abiomed , University Of South Carolina , Bristol Myers Squibb , Ablative Solutions , Harvard Medical School , Boston Scientific , Icahn School Of Medicine At Mount Sinai , Medtronic , Novo Nordisk , Corvia Medical , Northwestern University Feinberg School , Heart Failure Therapeutics , Mayo Clinic , Icahn School , Mount Sinai , New York City , North America , Kansas City Cardiomyopathy Questionnaire , Medical University , South Carolina , Axon Therapies , Impulse Dynamics , Quantum Genomics , Cardiac Dimensions , American Regent , Tenax Therapeutics , Miracor Medical , Apollo Therapeutics , Orchestra Biomed , Applied Therapeutics , Biostar Family , Cardiac Success , Cardiovascular Systems , Vascular Dynamics , Heart Failure , Exercise , Physical Activity , Right Heart Catheterization , Implanted Device Cardiology , Atrial Fibrillation , F Atrial Fibrillation , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Echocardiography , Echocardiogram , Echo , Cardiac Tamponade , Pericardial Tamponade , Ejection Fraction Ef , Eft Ventricular Ejection Fraction Lvef , Biomarker , Iological Marker , Stroke , Erebrovascular Acc ,